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The overuse of broad-spectrum
antibiotics has created a
tremendous human health
problem because bacteria are
becoming resistant to a wide
range of antibiotics, resulting in
the emergence of multidrug-
resistant ‘‘super bugs’’ requiring
selective drug treatment. The
problem is that selective drug use
requires highly equipped
laboratories to determine the best
drugs to be used. In this article, we
present a solution to this problemSUMMARY
Multidrug-resistant bacteria are amajor threat to human health, but broad-spec-
trumantibiotics are losing efficacy. There is a need to screen a given drug against
a bacterial infection outside of the laboratory. To address this need, we have de-
signed and built an inexpensive and easy-to-use 3D-printer-based system that
allows easily readable quantitative tests for the performance of antibacterial
drugs. The platform creates a sterile diagnostic device by using 3D printing,
and the device is filled automatically with growth medium, and then antibiotics
are sprayed onto the medium by ink-jet technology. The sample for testing can
be introduced via a fluid port, and the printer hot bed is used to incubate the de-
vice, allowing operation in the field. Combining advantages from various estab-
lished tests of antibacterial performance, this allows the comparison of a specific
antibiotics and bacteria. Also, this system can create and test several antibiotic
formulations for therapeutic use, and we demonstrate this potential by investi-
gating a mixture of pathogens that are only killed by a mixture of drugs.whereby we were able to develop
an inexpensive and autonomous
system that produces 3D-printed
diagnostic devices and is also
capable of incubating them if
needed, thereby leading to an
autonomous and integrated
system that can determine drug
effectiveness against bacterial
infection. This system is fully
automated and combines three
elements—plastic printing, gel
deposition, and drug (such as
antibiotics) spraying—by means
of an ink-jet array to yield fully
independent diagnostic units that
can be used in hospitals, in the
offices of general practitioners, at
home, or in the field.INTRODUCTION
The overuse of broad-spectrum antibiotics has created a tremendous problem
for the future of human health. This is because bacteria are gradually becoming resis-
tant to a wide range of antibiotics, resulting in the emergence of multidrug-resistant
microorganisms or ‘‘super bugs.’’1 Often, such super bugs have become resistant to
all but the most toxic drugs, and even these will soon be rendered useless.2 Thus,
previously trivial infections will increasingly prove to have potentially lethal conse-
quences, including a dramatic impact on all aspects of health care because even
routine hospital procedures could be fatal. Presently, several strategies are being
used to counter what is being described as the single biggest threat to human health
in the 21st century. These include the development of new drugs, which can take de-
cades, or the selective use of antibiotics rather than broad spectrum antibiotics to
prevent the development of drug-resistant bacteria. The critical problem is that se-
lective drug use requires efficient, cheap, and fast diagnostic tests to identify the
most effective drug, or combination of drugs, to ensure optimal treatment.3,4 Cur-
rent antibiotic testing takes time and requires a highly equipped laboratory and
trained personnel to first extract, culture, and subsequently isolate pathogens, which
can then be tested against several antibiotics. Wide testing therefore creates enor-
mous bottlenecks within hospitals and increased costs for patient care, as well as
potentially worse outcomes as a result of the delayed tests, which can have extreme
effects on a patient’s quality of life.
To explore this issue, we hypothesized that it should be possible to develop an inex-
pensive and autonomous system that produces a monolithic 3D-printed5 diagnostic494 Chem 1, 494–504, September 8, 2016 ª 2016 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Scheme 1. Diagram Showing How Our Autonomous System Produces the Device
Steps are as follows: (1) 3D printing (FDM) of the device (3 hr); (2) deposition of agar into all lanes
(2 min); (3) ink jetting of the antibiotic (2 min); (4) inflow of the pathogen via the fluidic port in the
3D-printed device is indicated by the blue arrow (1 min); (5) incubation (12 hr for E. coli);
(6) readout of the resulting bacterial clearing and information on choosing antibiotics for the next
test (2 min). In steps 1 and 5, the heat bed of the 3D printer is used for fixing the print during
printing (in step 1) and incubating the sample (in step 5). See Supplemental Information for a movie
of the process.
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http://dx.doi.org/10.1016/j.chempr.2016.08.008device capable of both incubating pathogens and testing drug efficacy, thereby
leading to an integrated system. The idea would be to have portable laboratory-
like test facilities that could be more spread out than hospitals but still in locations
where ease of access and repeat use would be possible. Using 3D printing in an
approach such as this lends many advantages, such as the ability to produce inher-
ently sterile structures (see below) with architectures that can be tailored to the indi-
vidual application, with fluidic channels and internal voids as necessary. As well as
being reconfigurable on demand to suit changing requirements, these structures
are produced from cheap, biodegradable materials. Indeed, the emergence of 3D
printing in health care is set to make a big impact.6–8 We propose a system that is
fully automated and built by a combination of three elements: plastic printing, gel
deposition, and drug spraying by an ink-jet array (Scheme 1).
RESULTS
Here, we present our efforts to design and build such a fully automated system. Our
system is simple to use, and it is a fully portable independent diagnostic unit that can
be used by untrained personnel in hospitals, in the offices of general practitioners, at
home, or in the field. Bacterial samples can easily be introduced at one inlet via fluid
injection and can be sampled in parallel over a number of lanes. The use of fused
deposition modeling (FDM) printing has the advantage of producing intricate flu-
idics not easily accessible with injectionmolding, and the resulting devices are intrin-
sically sterile because of the deposition temperature of the print. In addition, it is
easy to produce leak-free prints with the use of polylactic acid (PLA) in our configu-
ration, and the devices can be autoclaved and reused as needed. PLA was chosen as
a substrate for printing in our application because it is a cheap material with good
properties for ease of 3D printing in that it produces water-tight structures with
high fidelity to digital designs. Although other materials are available for FDM 3DChem 1, 494–504, September 8, 2016 495
printing, we find PLA to be more than adequate for the application we describe. Our
setup could, however, be used with other materials if required.
Normally, we needed only 0.2–0.3 mL of a 1 mL total bacterial sample volume. In this
study, we used bioluminescent bacteria to explore and quantify the efficacy of three
antibiotic drugs (kanamycin, tetracycline, and polymyxin B) against Escherichia coli.
Bioluminescentbacteria allowedus to follow theexperimenteasily asproof of principle,
but this is by nomeans necessary for the device to function (we show this to be the case
here also). Although this is difficult to convey in a photograph, the growth zones of bac-
teria are clearly visiblebyeye,because the reflectivity of the agar surfacechanges signif-
icantly when bacteria grow on it (i.e., tilting the device in the light shows where bacteria
have grown and where they have not). This approach can be used to identify bacteria
that havenot been transformed tobebioluminescent.Weused clearing zones to assess
the efficacy of the antibiotics. Thesemodel drugs effectively illustrate that the platform
presented here can explore different types of antibiotic modes of operation (e.g.,
bacteriostatic and bactericidal). This system also builds upon our recent development
of 3D-printed chemical ‘‘reactionware’’ for bespoke reagent and/or fluid control by us-
ing an easily accessible and configurable consumer 3D printer that can be customized
mechanically with open-source software.9–11
We have constructed a robotic platform based on a RepRap 3D printer12 and
expanded its capability to dispense gels and to handle very small amounts of liquid
with the use of ink-jet technology (see Figure 1). The Supplemental Information pro-
vides the details for users to modify their own RepRap, and source codes (software
and computer-aided designs) are freely available for non-profit use (STL files for the
modified 3D printer parts are also available from the authors). The robot uses a con-
ventional FDM 3D printer, in which a molten polymer is extruded through a 0.45 mm
nozzle and deposited in a layer-by-layer fashion to create the 3D-printed test device.
The operating principle of this type of 3D printing, in which polymers are heated to
between 180C and 350C depending on the polymer to be printed,13 produces
inherently sterile structures, an unexplored feature that is perfect for biological
applications because sterile conditions are a must. We propose that the devices
should be sealed to maintain sterility after manufacturing (like any sterile laboratory
consumable), or the whole system can be sterilized and placed in a suitably sterile
environment, such as a flow hood.
Traditionally, unknown bacterial pathogens are isolated and cultured to obtain an
antibiogram.14 Antibiograms can be obtained via agar diffusion, agar dilution, Etest,
and broth microdilution. The most common is a semi-quantitative agar diffusion test
that places paper discs infused with a particular antibiotic onto a bacterial lawn, and
then the effectiveness of the antibiotic is assessed by measurement of the clearing
diameter around the discs. Themain advantage of the disc test is the ability to assess
several antibiotics in parallel; however, it is not fully quantitative. The Etest was
developed to solve the semi-quantitative nature of disc tests. It is a simple system
utilizing a testing strip impregnated with an increasing concentration of the subject
antibiotic, allowing the minimal inhibitory concentration (MIC) of the antibiotic to be
determined. Other test methodologies, such as broth microdilution and agar dilu-
tion, yield quantitative results by exposing liquid or plated cultures to a serial dilu-
tion of antibiotics. However, to get quantitative results, most of these systems are
labor intensive and require specialized personnel.
Our approach combines the advantages of all methods described above by produc-
ing aligned diffusion tests in an automated setup, where individual antibiotics are496 Chem 1, 494–504, September 8, 2016
Figure 1. The 3D-Printer-Based Robotic Setup
(A) Image of the robotic setup: (A.1) computer, (A.2) webcam for monitoring, (A.3) PLA filament, and
(A.4) printing bed.
(B) Close-up of the control electronics and the agar pump: (B.1) motor driver for the pump, (B.2)
Arduino Mega 2560 Rev. 3 to control the pump, (B.3) ink shield on the Arduino Mega 2560 Rev. 3 to
control the ink cartridge, (B.4) pump built in house to dispense agar, (B.5) heating mantle to keep
the agar solution at 70C, and (B.6) temperature controller for the heating mantle.
(C) Close-up of the carriage: (C.1) ink cartridge filled with antibiotic solution, (C.2) needle for
dispensing the agar, (C.3) hot end for the FDM 3D printing process, and (C.4) the printed device.deposited via ink-jet printing onto aligned lanes of agar rather than one large Petri
dish. The amount of antibiotic deposited can be tuned by varying the spray time,
eliminating the need to produce test solutions of different concentrations. The
aligned nature of the diffusion test makes comparison between different concentra-
tions of the same antibiotic possible by eye rather than requiring a measurement.
The fact that any amount of antibiotic can be supplied as needed makes it feasible
to determine theMIC of different antibiotics in an automated fashion. This allows de-
cisions about treatments, potentially avoiding overuse of broad-spectrum antibi-
otics or validation of potential combination therapies on demand.
For the purposes of our study presented here, we designed a device with four
chambers (1 cm 3 5 cm; Figure 2), each connected with a channel to the same inlet
port and filled by the robot with a growth medium, typically an agar gel. However,
the number of chambers can easily be modified. Once the gel is deposited in the
test chambers, the antibiotic is automatically sprayed into the chamber. Either
different amounts of the same antibiotic or three different antibiotics plus a blank
test are sprayed. Typically, preparing a device requires 4 hr, but this could be
reduced significantly with simple optimizations, such as reduction of overall device
size, more lanes per device (which would reduce the per-lane print time), fewer
lanes per device (e.g., if only two antibiotics are to be compared), or a more sophis-
ticated printer that can print at higher speeds if required (Scheme 1). In the final
step, the device is covered with a 3D-printed lid. A full technical description of
the robot and modes of operation, as well as the source code, 3D models, and or-
der codes for all components, can be found in the Supplemental Information (see
sections ‘‘Robot Design and Construction’’ and ‘‘Process Control Software,’’ Figures
S1–S4, and Schemes S1–S3). We found the printed devices to be robust with noChem 1, 494–504, September 8, 2016 497
Figure 2. Stages of the Device from Design to Real Use
(A) Visualization of the device design.
(B) The printed device.
(C) The device after the robot deposited the agar and the antibiotic.
(D) The device in the dark with bioluminescent bacteria.evidence of leakage of either growth medium or bacterial culture in any of our
experiments.
To demonstrate the applicability of these devices as performance tests for antibi-
otics, we selected E. coli DH5a and investigated several methods for assessing
antibiotic performance. As model systems, we tested three antibiotics: kanamycin,
tetracycline, and polymyxin B. They were chosen because they represent three
different modes of operation; kanamycin is an aminoglycoside bactericidal anti-
biotic,15 tetracycline is a broad-spectrum bacteriostatic antibiotic,16 and polymyxin
B is a bactericidal amphiphile that destroys the cell membrane of gram-negative
bacteria.17,18 These three antibiotics require different solvent compositions. Kana-
mycin is soluble in water, tetracycline is soluble in water/ethanol mixtures (here,
we used a stock solution of 5 mg/mL in 70% EtOH/H2O, which was subsequently
diluted with sterile water to produce the desired concentrations), and polymyxin B
is a surfactant in water. To aid our test experiments by visualizing growth, we used
E. coli that was engineered to become bioluminescent and resistant to ampicillin
by transformation of pXen13 (PerkinElmer) plasmid (Figure 3; the full experimental
procedure is provided in the Supplemental Information). This provides a test that
can assess metabolic activity because only the living bacteria are bioluminescent.
Here, we found that for the strain of E. coli used, the clearing per antibiotic
followed the expected trend for diffusion in gels. Importantly, we were also able
to easily see bacterial growth by eye without the need for bioluminescence, allowing
us to further validate the potential of this approach for widespread use in the field
(Figure 3). For general use of our system, it would be impractical to use only bacteria
that had been transformed to be bioluminescent; therefore, visual identification of
the extent of bacterial growth should be seen as the standard approach for this tech-
nique. The transformed bacteria were used only to confirm that the areas of bacterial
growth identified visually were coincident with the areas of bacterial metabolic
activity.498 Chem 1, 494–504, September 8, 2016
Figure 3. Inhibition Tests with Tetracycline
(A) Lanes from left to right: (A.1) ampicillin control (negative test) and 1/5 diluted tetracycline stock
sprayed for 2 s (scale bar represents 50 mm), 4 s (scale bar represents the measured bacterial
clearing due to antibiotic activity), and 8 s; (A.2) the same test plate as in (A.1) but photographed in
the dark; (A.3) summary of clearing experiments measured in the light (red circles) and dark (black
squares) with various amounts of tetracycline. The mean clearing was taken from at least six
experiments, and error bars represent the SEM (see section ‘‘Tetracycline Experiments’’ in the
Supplemental Information for the full procedure).
(B) Inhibition tests with kanamycin. Lanes from left to right: (B.1) ampicillin control (negative test)
and 1/5 diluted kanamycin stock sprayed for 2 s, 4 s (scale bar represents the measured bacterial
clearing due to antibiotic activity), and 8 s; (B.2) the same test plate as in (B.1) but photographed in
the dark; (B.3) summary of the clearing experiments measured in the light (red circles) and dark
(black squares) with various amounts of kanamycin. The mean clearing was taken from at least six
experiments, and error bars represent the SEM (see section ‘‘Kanamycin Experiments’’ in the
Supplemental Information for the full procedure). Images A.1 and B.1 were converted to grayscale
and contrast enhanced so the bacterial lawn would be more visible in the photographs. When
viewed by eye, the edge of the bacterial clearing was easily visible. For comparison, see the original
full-sized photographs in Figure S10. The spray point of the antibiotic is indicated for one lane in
both light photographs (blue broken circle), and the clearing measurement is also indicated (blue
bar). For the full procedure, see the Supplemental Information.Weare able todeposit different amounts of antibiotic ranging from0.02 to 43.5 mgon
to thegel to assess bacterial susceptibility (Figure 3). For example, kanamycin cleared
an average of 24.2G0.68mmat 37.1 mgdeposition. Tetracycline cleared an average
of 27.5G3.4mmat a deposition of 43.5mg (G represents the SEM). The clearingpro-
files and reported variation in clearing matched the expected clearing measure-
ments. However, we were unable to get consistent clearing of polymyxin B because
of its surfactant nature (Figure S22). In addition, experiments to further assess
different approaches for evaluating the performance of antibiotics were conducted.
In each case, one of the four lanes of the device was used as a negative control, i.e.,
only ampicillin was added to the agar to prevent contamination. The other lanes were
treated with the same amount (30 mg each) of different antibiotics for comparison ofChem 1, 494–504, September 8, 2016 499
their effectiveness (Figure S23). Two different antibiotics, kanamycin and tetracy-
cline, showed different clearances of E. coli at the same nominal concentration.
Although this is not unexpected, given that the MICs of all three antibiotics are
different, it illustrates nicely how comparing the clearing by eye becomes much
easier in linear arrangements than in common circular clearings (Figure S25 illustrates
this). This demonstrates not only that this approach offers the same capability as the
classic agar diffusion test but also that the linear arrangement of the test lanes allows
much quicker and easier readout of results. Moreover, it is trivial to add a pre-cali-
brated ruler to the 3D model of the dish to aid quantitative analysis of the clearing.
To investigate reusability, we autoclaved the printed devices three times and found
no considerable degradation (i.e., deformation to a degree that would make a ruler
too inaccurate). In a second set of experiments, three lanes of the device were
sprayed with different solution volumes of the same antibiotic concentration (wt %)
or with the same solution volumes of different antibiotic concentrations. This was
to establish the amount of antibiotic that the microorganism would be susceptible
to (Figure 3). This approach provides a test to ensure that the mode of deposition
does not influence the result of the experiment. A given amount of antibiotic was
deposited three different ways: (1) spraying an antibiotic solution of low concentra-
tion for a long time (i.e., depositing 2.32 mg by spraying a 1 mg/mL antibiotic solution
for 4 s), (2) spraying an antibiotic solution of high concentration for a short time (i.e.,
depositing 2.32 mg by spraying a 2 mg/mL antibiotic solution for 2 s), and (3) spraying
an antibiotic solution of low concentration several times for short periods and drying
the drop in between (e.g., depositing 18.56 mg of kanamycin [2 mg/mL] by spraying
several times for a short amount of time [4 s] and letting the droplet dry for 2 min
in between). The third deposition method ensures that the larger droplet created
by spaying for a long time does not alter the result of the test (see Figure 4 and Sup-
plemental Information section ‘‘Statistical Analysis of Different AB Deposition
Modes’’). None of the modes of deposition altered the clearing data we collected,
and only the total amount of antibiotic deposited determined the clearing distance
(see Supplemental Information section ‘‘Antibiotic Experiment Analysis’’). To rigor-
ously verify this, we performed various statistical analyses on sets of obtained data
by spraying 1.16, 2.32, 4.64, 9.28, 18.56, and 37.12 mg of kanamycin. See section
‘‘Statistical Analysis of Different ABDepositionModes’’ in the Supplemental Informa-
tion for graphs and a more extensive description of the tests.
These tests yielded results well within the margin of error of commercially available
antibiotic test discs (BD Sensi-Discs), which state a variability of 8 mm in clearing,
providing all the advantages of quantitative testing. To determine the amount of
antibiotic deposited, we created calibration curves for the respective solvent com-
positions by spraying pure solvent onto glass slides and weighing them after various
spraying times. The deposition of pure solvent was found to be 579 and 654 mg/s for
water and 14% ethanol in water, respectively; in both cases, the deposition was
linear with time (Figures S6 and S7). The increase in deposition for a mixed solvent
is expected given the nature of the ink cartridge, which is designed to flash evapo-
rate ink that has a volatile component.
Finally, as a proof of concept, we did an experiment where only a combination of
different antibiotics would result in complete clearing of the pathogens. This
allowed us to explore a case where a sample has multiple pathogens, which would
be useful when a patient has multiple infections. Alternatively, we could also investi-
gate the conditions under which only one type of bacteria needs to be eliminated
while another given bacteria should be left unaffected. To do this experiment,500 Chem 1, 494–504, September 8, 2016
Figure 4. Comparison of the Clearing Data Obtained from Different Modes of Depositing the
Same Amount of Kanamycin
(A) Histograms of the raw data are overlaid with kernel smooth plots generated with OriginPro
2015 SR1.
(B) Plots comparing kernel density include 95% confidence intervals (gray shaded areas) produced
with sm.density.compare from the sm package in R (see section ‘‘Statistical Analysis of Different AB
Deposition Modes’’ in the Supplemental Information for full details).we did not add ampicillin to the growth medium, and the LB agar was replaced with
Bluo-gal and isopropyl b-D-1-thiogalactopyranoside (100 and 4 mg/mL, respectively;
both from Life Technologies). The medium was deposited as in the previous exper-
iments. We left the leftmost lane blank to see whether any contaminants would grow.
Ampicillin (100 mg/mL) was sprayed for 16 s in the next lane, kanamycin (2 mg/mL) was
sprayed for 16 s in the adjacent lane, and both ampicillin and kanamycin were
sprayed for 16 s on top of each other in the final lane. A total volume of 60 mL of
E. coli culture at a ratio of 6:1 (pXen13:pHSG299) was added into each lane, and
the bacteria were allowed to grow overnight at 37C. As a result, each of the two cen-
ter lanes cleared only one of the two pathogens, and only the rightmost lane cleared
both (see section ‘‘Antibiotic Formulation’’ in the Supplemental Information and Fig-
ure S26). As a final test, we compared the performance of the presented apparatus
and methodology with that of commercial disc tests by spraying the same amount
of antibiotic contained in a disc directly onto one of the lanes of the device (Figure 5).
Here, the antibiotic that was sprayed cleared slightly more (15% for kanamycin and
14% for tetracycline, each at 30 mg; Figure S24) than an antibiotic disc. This is ex-
plained by the fact that the solution of antibiotic diffuses directly into the agar
when deposited and becomes fully effective, whereas an infused disc itself acts asChem 1, 494–504, September 8, 2016 501
Figure 5. Comparison of a Commercially Available Antibiotic Disc Test with the Robotic Setup
From left to right, the first lane (contr.) constitutes the negative test, containing only ampicillin. The
second lane (empty) was unused for this experiment. In the third spray lane, 30 mg of tetracycline
was sprayed down. In the last disc lane, a paper disc infused with 30 mg of tetracycline was placed at
the same height as the sprayed antibiotic. Lanes are shown both in the light (A) and in the dark (B).
The image in (A) was converted to grayscale and contrast enhanced so the bacterial lawn would be
more visible in the photographs. When viewed by eye, the edge of the bacterial clearing was easily
visible. For comparison, see original full-sized photographs in Figure S24.a diffusion barrier, preventing it from releasing all of the antibiotic contained in the
disc into the gel underneath. This illustrates not only that discs have their own draw-
back of being a physical object obstructing the observation of very small amounts of
clearance (i.e., the minimal observable diameter is slightly larger than the physical
diameter of the disc) but also that the concentration of antibiotic actually present
in the agar is not precisely known. The use of defined agar lanes yields a better
spatial resolution of the clearance because diffusion does not occur in a circular
fashion; rather, the locally high concentration at the disc or spray point diffuses
quasi-linearly down the lanes. This steeper gradient causes the antibiotics to diffuse
further and hence results in better resolution of the clearing or a faster result because
small clearings become visible earlier. For the BBL Sensi-Disc with 30 mg of kana-
mycin, the expected clearance stated by the manufacturer for E. coli (ATCC
25922) is 17–25 mm in diameter (i.e., 8.5–12.5 mm from the center of the disc; see
section ‘‘Comparison with Commercial Disc Tests’’ in the Supplemental Informa-
tion), whereas it cleared 20.7 mm in our lanes. The same was observed when we
sprayed the antibiotic. On circular Petri dishes, the disc with the sprayed antibiotic
cleared a circle of a 12.75 mm radius, and in the lanes, the clearing extended
23.55 mm from the center.DISCUSSION
In conclusion, we have developed an autonomous robotic system that combines 3D
printing, gel deposition, and ink-jet technologies into a unified platform. We used
this system to determine and compare the antibacterial activity of three standard
antibiotic agents with different mechanisms of action, similar to standard disc diffu-
sion systems. The robotic platformwas used to 3D print a bespoke test device, which
was filled with growthmedium via a syringe-based liquid handling system, and finally
microgram quantities of the antibacterial agents were deposited by an ink-jet pro-
cess. This system, which involves one automated, small-form-factor device that502 Chem 1, 494–504, September 8, 2016
does not need expert operation and can be used virtually anywhere at a very low cost
($0.10 per test),19 was found to replicate and surpass many aspects of the tradi-
tional techniques, especially in the ability to use one antibiotic solution
‘‘cartridge’’ to accurately deposit any desired quantity of material for testing.
Furthermore, the use of PLA as a print material did not give any issues with leaking
or absorption of water from the environment during our studies.20
Beyond the experimental results presented here, we envisage that our system’s’
design could enable many further modes of operation to address a range of other
possible applications. Although a single self-contained test might be useful in a
research laboratory, in a hospital environment, the robot could be used to mass pro-
duce test devices that are placed onto the robot again when needed and are only
then filled with fresh agar and antibiotic (see section ‘‘Process Control Software’’ in
the Supplemental Information for a detailed explanation of the different modes of
operation). The advantage of decoupling device printing from agar and antibiotic
filling is that the actual test is sped up considerably. With pre-printed and autoclaved
test devices, we easily achieved 128 single tests performed by one person in less than
one working day (without incubation time; see Figure S4 for an image of a stack of
plates prepared in a few hours). Additionally, it would be reasonable to mimic the
procedure of the standard reference agar dilution test by using the ink-jet to deposit
a well-defined layer of antibiotic and then seeding several pathogens per lane.More-
over, the robot could assist the classic broth microdilution test because microgram
amounts of antibiotics can be added on demand. Because of the precision of the
ink-jet process, it would take just minutes to produce a full dilution series from a sin-
gle cartridge of known concentration. Lastly, in addition to being able to cover many
existing testmethodologies in one single automated apparatus, the setup presented
can be used to easily produce any mixed antibiotic formulation (Figure S26); which
would be impossible with discs or Etests and would make the already labor-intensive
broth microdilution or agar dilution more cumbersome. Mixing any number of anti-
biotics can then be achieved like dialing up a color on a standard ink-jet printer that
mixes the different colors from the cartridges to give the required ink ratio.
We believe that researchers and clinicians can use this open hardware platform to
quickly screen antibiotics or even assess entirely new formulations by any of the es-
tablished techniques in a fully automated fashion. We envisage that this system can
be extended to in-the-field discovery of the best antibiotic therapy to be used on a
per infection basis. This system is another step in the use of integrated open technol-
ogies for exploring diagnostic hybrid biomaterial devices.21 In this case, we believe
the system could become an important open-source22 approach in the fight against
antibiotic-resistant microbes because the use of 3D printers and open-source soft-
ware means that such configurable diagnostics could be deployed on a global scale
for a fraction of the current cost.EXPERIMENTAL PROCEDURES
Because the construction of the robotic platform and the programming thereof
require a long and detailed technical description, please refer to the Supplemental
Information, which includes 3D models and source code for all programs.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, 27 fig-
ures, 15 tables, 3 schemes, and 1 movie and can be found with this article online at
http://dx.doi.org/10.1016/j.chempr.2016.08.008.Chem 1, 494–504, September 8, 2016 503
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